Literature DB >> 31782083

Eukaryotic initiation factor 4E is a novel effector of mTORC1 signaling pathway in cross talk with Mnk1.

Asiya Batool1, Sheikh Tahir Majeed1, Sabreena Aashaq1, Rabiya Majeed1, Nadiem Nazir Bhat1, Khurshid Iqbal Andrabi2.   

Abstract

Cellular signals that influence Cap-dependent translation have assumed significant relevance in the backdrop of their enforced dysregulation during oncogenesis. Eukaryotic initiation factor 4E(eIF4E), the mRNA cap-binding protein, has emerged as a key player to facilitate tumor progression through upregulated cap-dependent translation synchronized with enhanced cell division. We provide evidence that eIF4E phosphorylation is regulated by mTORC1 by virtue of its interaction with Raptor through a novel TPTPNPP motif and consequent phosphorylation invitro and in vivo in a Rapamycin-sensitive manner. While we show that phosphorylation pattern of eIF4E responds faithfully to Rapamycin inhibition, the prolonged exposure to Rapamycin rescues the loss of eIF4E phosphorylation through Mnk1 activation. We also present evidence that eIF4E interacts with the amino terminal domain of S6K1 in a phospho-dependent manner, and this interaction is instrumental in overriding Rapamycin inhibition of S6K1. The data endorses eIF4E as a regulatory subunit that modulates the functional attributes of mTOR effectors to synchronize cap-dependent translation with growth assertion.

Entities:  

Keywords:  4E-BP1; Mnk1; Rapamycin; Translation; eIF4E; mTORC1

Mesh:

Substances:

Year:  2019        PMID: 31782083     DOI: 10.1007/s11010-019-03663-z

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  53 in total

1.  eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression.

Authors:  Luc Furic; Liwei Rong; Ola Larsson; Ismaël Hervé Koumakpayi; Kaori Yoshida; Andrea Brueschke; Emmanuel Petroulakis; Nathaniel Robichaud; Michael Pollak; Louis A Gaboury; Pier Paolo Pandolfi; Fred Saad; Nahum Sonenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

2.  Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2.

Authors:  A J Waskiewicz; A Flynn; C G Proud; J A Cooper
Journal:  EMBO J       Date:  1997-04-15       Impact factor: 11.598

3.  Two motifs in the translational repressor PHAS-I required for efficient phosphorylation by mammalian target of rapamycin and for recognition by raptor.

Authors:  Kin Man Choi; Lloyd P McMahon; John C Lawrence
Journal:  J Biol Chem       Date:  2003-03-28       Impact factor: 5.157

4.  MNK Controls mTORC1:Substrate Association through Regulation of TELO2 Binding with mTORC1.

Authors:  Michael C Brown; Matthias Gromeier
Journal:  Cell Rep       Date:  2017-02-07       Impact factor: 9.423

5.  Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy.

Authors:  Xuerong Wang; Natalyn Hawk; Ping Yue; John Kauh; Suresh S Ramalingam; Haian Fu; Fadlo R Khuri; Shi-Yong Sun
Journal:  Cancer Biol Ther       Date:  2008-12-08       Impact factor: 4.742

6.  eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival.

Authors:  Jeremy R Graff; Bruce W Konicek; Rebecca L Lynch; Chad A Dumstorf; Michele S Dowless; Ann M McNulty; Stephen H Parsons; Leslie H Brail; Bruce M Colligan; Jonathan W Koop; Bernadette M Hurst; James A Deddens; Blake L Neubauer; Louis F Stancato; Harry W Carter; Larry E Douglass; Julia H Carter
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

Review 7.  eIF-4E expression and its role in malignancies and metastases.

Authors:  Arrigo De Benedetti; Jeremy R Graff
Journal:  Oncogene       Date:  2004-04-19       Impact factor: 9.867

8.  Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues.

Authors:  Songqing Fan; Suresh S Ramalingam; John Kauh; Zhiheng Xu; Fadlo R Khuri; Shi-Yong Sun
Journal:  Cancer Biol Ther       Date:  2009-08-08       Impact factor: 4.742

9.  Control of eIF4E cellular localization by eIF4E-binding proteins, 4E-BPs.

Authors:  Liwei Rong; Mark Livingstone; Rami Sukarieh; Emmanuel Petroulakis; Anne-Claude Gingras; Katherine Crosby; Bradley Smith; Roberto D Polakiewicz; Jerry Pelletier; Maria A Ferraiuolo; Nahum Sonenberg
Journal:  RNA       Date:  2008-05-30       Impact factor: 4.942

10.  CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.

Authors:  Qiuyuan Wen; Weiyuan Wang; Jiadi Luo; Shuzhou Chu; Lingjiao Chen; Lina Xu; Hongjing Zang; Mohannad Ma Alnemah; Jian Ma; Songqing Fan
Journal:  Oncotarget       Date:  2016-05-10
View more
  4 in total

1.  mTORC1 induces eukaryotic translation initiation factor 4E interaction with TOS-S6 kinase 1 and its activation.

Authors:  Sheikh Tahir Majeed; Asiya Batool; Rabiya Majeed; Nadiem Nazir Bhat; Muhammad Afzal Zargar; Khurshid Iqbal Andrabi
Journal:  Cell Cycle       Date:  2021-05-03       Impact factor: 4.534

2.  High-throughput translational profiling with riboPLATE-seq.

Authors:  Jordan B Metz; Nicholas J Hornstein; Sohani Das Sharma; Jeremy Worley; Christian Gonzalez; Peter A Sims
Journal:  Sci Rep       Date:  2022-04-05       Impact factor: 4.379

3.  The Sphingolipid Inhibitors Ceranib-2 and SKI-II Reduce Measles Virus Replication in Primary Human Lymphocytes: Effects on mTORC1 Downstream Signaling.

Authors:  Janice Chithelen; Hannah Franke; Nora Länder; Anika Grafen; Jürgen Schneider-Schaulies
Journal:  Front Physiol       Date:  2022-03-17       Impact factor: 4.566

4.  Low-Level Ionizing Radiation Induces Selective Killing of HIV-1-Infected Cells with Reversal of Cytokine Induction Using mTOR Inhibitors.

Authors:  Daniel O Pinto; Catherine DeMarino; Thy T Vo; Maria Cowen; Yuriy Kim; Michelle L Pleet; Robert A Barclay; Nicole Noren Hooten; Michele K Evans; Alonso Heredia; Elena V Batrakova; Sergey Iordanskiy; Fatah Kashanchi
Journal:  Viruses       Date:  2020-08-13       Impact factor: 5.818

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.